Exclusive: Is Selling Aduro BioTech Inc Here a Winning Strategy?

Exclusive: Is Selling Aduro BioTech Inc Here a Winning Strategy?

The stock of Aduro BioTech Inc (NASDAQ:ADRO) is a huge mover today! About 140,974 shares traded hands. Aduro BioTech Inc (NASDAQ:ADRO) has declined 9.22% since April 27, 2016 and is downtrending. It has underperformed by 14.45% the S&P500.
The move comes after 7 months negative chart setup for the $761.98 million company. It was reported on Nov, 30 by Barchart.com. We have $11.06 PT which if reached, will make NASDAQ:ADRO worth $30.48 million less.

Analysts await Aduro BioTech Inc (NASDAQ:ADRO) to report earnings on March, 14. They expect $-0.38 earnings per share, down 1,050.00% or $0.42 from last year’s $0.04 per share. After $-0.54 actual earnings per share reported by Aduro BioTech Inc for the previous quarter, Wall Street now forecasts -29.63% EPS growth.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Out of 6 analysts covering Aduro Biotech (NASDAQ:ADRO), 3 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 50% are positive. Aduro Biotech has been the topic of 9 analyst reports since August 19, 2015 according to StockzIntelligence Inc. As per Thursday, August 27, the company rating was maintained by Roth Capital. The company was initiated on Tuesday, October 20 by Oppenheimer. As per Tuesday, December 1, the company rating was downgraded by Oppenheimer. The firm has “Buy” rating given on Tuesday, November 24 by Roth Capital. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “Underperform” rating by Bank of America on Tuesday, March 15. FBR Capital maintained the shares of ADRO in a report on Tuesday, May 17 with “Outperform” rating. The stock of Aduro BioTech Inc (NASDAQ:ADRO) earned “” rating by Leerink Swann on Wednesday, August 19. The firm has “Hold” rating given on Thursday, September 3 by Zacks. The company was maintained on Tuesday, November 24 by TH Capital.

According to Zacks Investment Research, “Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is based in BERKELEY, United States.”

More recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: Marketwatch.com which released: “Aduro Biotech stock drops as much as 22% after patient tested positive for …” on October 24, 2016. Also Fool.com published the news titled: “Why Aduro Biotech Is Crashing Today” on November 24, 2015. Globenewswire.com‘s news article titled: “Aduro Biotech Reports Partial Clinical Hold to Pause Enrollment in LADD Trials” with publication date: October 24, 2016 was also an interesting one.

ADRO Company Profile

Aduro Biotech, Inc., incorporated on May 5, 2011, is a clinical-stage immunotherapy company. The Firm is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Firm has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies. The Company’s LADD technology platform is engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, LADD technology platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. The Company’s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a tumor-specific immune response. The Company’s B-select monoclonal antibody platform includes various immune modulating assets in research and preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment